Population Pharmacokinetics and Exposure‐Response Analyses to Guide Dosing of Icatibant in Pediatric Patients With Hereditary Angioedema

Elevated bradykinin levels are responsible for the development of clinical symptoms in patients with hereditary angioedema (HAE). Icatibant is a bradykinin type 2 receptor antagonist indicated for the acute treatment of HAE attacks. A population modeling and simulation approach was used to examine s...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yi, Jomphe, Claudia, Marier, Jean‐Francois, Martin, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Pediatric Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984404/
https://www.ncbi.nlm.nih.gov/pubmed/33091166
http://dx.doi.org/10.1002/jcph.1768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984404/
https://www.ncbi.nlm.nih.gov/pubmed/33091166
http://dx.doi.org/10.1002/jcph.1768

Ejemplares similares